A

Adverum Biotechnologies
D

ADVM

2.29500
USD
0.04
(1.55%)
مغلق
حجم التداول
914
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
47,944,232
أصول ذات صلة
A
ALLO
-0.00500
(-0.42%)
1.18500 USD
BMRN
BMRN
0.560
(0.98%)
57.750 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
S
SRPT
0.010
(0.06%)
18.200 USD
V
VYGR
0.00000
(0.00%)
3.20000 USD
المزيد
الأخبار المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.